238 related articles for article (PubMed ID: 23733767)
21. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero G; Roboz G; Walsh K; Kantarjian H; Ritchie E; Kropf P; O'Connell C; Tibes R; Lunin S; Rosenblat T; Yee K; Stock W; Griffiths E; Mace J; Podoltsev N; Berdeja J; Jabbour E; Issa JJ; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2019 Jun; 6(6):e317-e327. PubMed ID: 31060979
[TBL] [Abstract][Full Text] [Related]
22. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy.
Wu W; Lin Y; Xiang L; Dong W; Hua X; Ling Y; Li H; Yan F; Xie X; Gu W
Ann Hematol; 2016 Jun; 95(7):1051-7. PubMed ID: 27116384
[TBL] [Abstract][Full Text] [Related]
23. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Welch JS; Petti AA; Miller CA; Fronick CC; O'Laughlin M; Fulton RS; Wilson RK; Baty JD; Duncavage EJ; Tandon B; Lee YS; Wartman LD; Uy GL; Ghobadi A; Tomasson MH; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Cashen AF; Schroeder MA; Jacoby MA; Heath SE; Luber K; Janke MR; Hantel A; Khan N; Sukhanova MJ; Knoebel RW; Stock W; Graubert TA; Walter MJ; Westervelt P; Link DC; DiPersio JF; Ley TJ
N Engl J Med; 2016 Nov; 375(21):2023-2036. PubMed ID: 27959731
[TBL] [Abstract][Full Text] [Related]
24. Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.
Li H; Wang L; Wu Y; Su L; Zhao H; Zhang Y; Wang Z; Huang D; Huang Z; Wu X; Li X; Ye F; Yu F; Liu H; Wang JW; Cong J; Sun W; Chen HR; Wang J; Han B
Acta Haematol; 2017; 138(3):168-174. PubMed ID: 29045939
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
Liu W; Zhou Z; Chen L; Wang X
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
[TBL] [Abstract][Full Text] [Related]
26. Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Gao S; Li Z; Fu JH; Hu XH; Xu Y; Jin ZM; Tang XW; Han Y; Chen SN; Sun AN; Wu DP; Qiu HY
Asian Pac J Cancer Prev; 2015; 16(15):6627-32. PubMed ID: 26434886
[TBL] [Abstract][Full Text] [Related]
27. [Decitabine treatment in myelodysplastic syndromes--results of a compassionate patient program in Israel].
Klepfish A; Silbershatz I; Lugassy G; Shimoni A; Mittelman M
Harefuah; 2013 Oct; 152(10):591-4, 624. PubMed ID: 24450031
[TBL] [Abstract][Full Text] [Related]
28. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
29. A comparison of therapeutic dosages of decitabine in treating myelodysplastic syndrome: a meta-analysis.
Yang B; Yu R; Cai L; Chi X; Liu C; Yang L; Wang X; He P; Lu X
Ann Hematol; 2017 Nov; 96(11):1811-1823. PubMed ID: 28842789
[TBL] [Abstract][Full Text] [Related]
30. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
31. Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies.
Savona MR; Kolibaba K; Conkling P; Kingsley EC; Becerra C; Morris JC; Rifkin RM; Laille E; Kellerman A; Ukrainskyj SM; Dong Q; Skikne BS
Am J Hematol; 2018 Oct; 93(10):1199-1206. PubMed ID: 30016552
[TBL] [Abstract][Full Text] [Related]
32. [The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate- or higer-risk myelodysplastic syndromes in the elderly patients].
Ai H; Wei XD; Yin QS; Wang P; Mi RH; Yuan FF; Chen L; Song YP
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):606-609. PubMed ID: 28789495
[TBL] [Abstract][Full Text] [Related]
33. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
Xie M; Jiang Q; Xie Y
Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
[TBL] [Abstract][Full Text] [Related]
34. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.
Issa JJ; Roboz G; Rizzieri D; Jabbour E; Stock W; O'Connell C; Yee K; Tibes R; Griffiths EA; Walsh K; Daver N; Chung W; Naim S; Taverna P; Oganesian A; Hao Y; Lowder JN; Azab M; Kantarjian H
Lancet Oncol; 2015 Sep; 16(9):1099-1110. PubMed ID: 26296954
[TBL] [Abstract][Full Text] [Related]
36. Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
Zhang Z; Chang CK; He Q; Guo J; Tao Y; Wu LY; Xu F; Wu D; Zhou LY; Su JY; Song LX; Xiao C; Li X
Leuk Lymphoma; 2017 Apr; 58(4):969-978. PubMed ID: 27686004
[TBL] [Abstract][Full Text] [Related]
37. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM
Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333
[TBL] [Abstract][Full Text] [Related]
38. Decitabine: An effective and safe treatment for myelodysplastic syndrome and acute myeloid leukemia.
Feng X; Chen X; Nie S; Chang Y; Meng F; Zhou J; Mao C; Li T; Yan X; Huang J; Liu S; Gao Y; Xiao S
J Cancer Res Ther; 2019; 15(7):1471-1476. PubMed ID: 31939424
[TBL] [Abstract][Full Text] [Related]
39. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.
Ali AM; Weisel D; Gao F; Uy GL; Cashen AF; Jacoby MA; Wartman LD; Ghobadi A; Pusic I; Romee R; Fehniger TA; Stockerl-Goldstein KE; Vij R; Oh ST; Abboud CN; Schroeder MA; Westervelt P; DiPersio JF; Welch JS
Cancer Med; 2017 Dec; 6(12):2814-2821. PubMed ID: 29058375
[TBL] [Abstract][Full Text] [Related]
40. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Wei Y; Xiong X; Li X; Lu W; He X; Jin X; Sun R; Lyu H; Yuan T; Sun T; Zhao M
Cancer Sci; 2021 Sep; 112(9):3636-3644. PubMed ID: 34185931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
